Identification of BMP2 as an epigenetically silenced growth inhibitor in rhabdomyosarcoma

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1727-1735

  Wolf, Sebastian ^a   Hagl, Beate ^a   Kappler, Roland ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bone morphogenetic protein 2; Expression; Methylation; Promoter; Rhabdomyosarcoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; BONE MORPHOGENETIC PROTEIN 2;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; BMP2 GENE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHABDOMYOSARCOMA;

BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEINS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

EID: 84899113456     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2312     Document Type: Article

References (55)

1. Paulino AC and Okcu MF: Rhabdomyosarcoma. Curr Probl Cancer 32: 7-34, 2008.
2. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-630, 1995.
3. Meyer WH and Spunt SL: Soft tissue sarcomas of childhood. Cancer Treat Rev 30: 269-280, 2004.
4. Newton WA Jr, Soule EH, Hamoudi AB, Reiman HM, Shimada H, Beltangady M and Maurer H: Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 6: 67-75, 1988.
5. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ and Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20: 2672-2679, 2002.
6. Loh WE Jr, Scrable HJ, Livanos E, Arboleda MJ, Cavenee WK, Oshimura M and Weissman BE: Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 89: 1755-1759, 1992.
7. Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20: 5736-5746, 2001.
8. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG and Rauscher FJ III: The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15: 1522-1535, 1995.
9. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
10. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD and Gazdar AF: Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21: 4345-4349, 2002.
11. Wong IH, Chan J, Wong J and Tam PK: Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 10: 994-1002, 2004.
12. Sugawara W, Haruta M, Sasaki F, Watanabe N, Tsunematsu Y, Kikuta A and Kaneko Y: Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 49: 240-249, 2007.
13. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators of bone formation: molecular clones and activities. Science 242: 1528-1534, 1988.
14. Lyons KM, Hogan BL and Robertson EJ: Colocalization of BMP 7 and BMP 2 RNAs suggests that these factors cooperatively mediate tissue interactions during murine development. Mech Dev 50: 71-83, 1995.
15. Duprez DM, Coltey M, Amthor H, Brickell PM and Tickle C: Bone morphogenetic protein-2 (BMP-2) inhibits muscle development and promotes cartilage formation in chick limb bud cultures. Dev Biol 174: 448-452, 1996.
16. Narita T, Saitoh K, Kameda T, Kuroiwa A, Mizutani M, Koike C, Iba H and Yasugi S: BMPs are necessary for stomach gland formation in the chicken embryo: a study using virally induced BMP-2 and Noggin expression. Development 127: 981-988, 2000.
17. Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors 22: 233-241, 2004.
18. Hollnagel A, Oehlmann V, Heymer J, Ruther U and Nordheim A: Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem 274: 19838-19845, 1999.
19. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ and Sutherland RL: Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59: 234-242, 2004.
20. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD and Izbicka E: Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9: 327-331, 1998.
21. Kawamura C, Kizaki M and Ikeda Y: Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma 43: 635-639, 2002.
22. Zhao H, Ayrault O, Zindy F, Kim JH and Roussel MF: Posttranscriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev 22: 722-727, 2008.
23. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
24. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M, Freneaux P, Pritchard-Jones K, Oberlin O, Shipley J and Delattre O: Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28: 2151-2158, 2010.
25. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM and Scarpa A: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28: 245-55, 2010.
26. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1: R50-R59, 2007.
27. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
28. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
29. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61: 7277-7281, 2001.
30. Yoon JH, Dammann R and Pfeifer GP: Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94: 212-217, 2001.
31. Dammann R, Yang G and Pfeifer GP: Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61: 3105-3109, 2001.
32. Nakaoka T, Gonda K, Ogita T, Otawara-Hamamoto Y, Okabe F, Kira Y, Harii K, Miyazono K, Takuwa Y and Fujita T: Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100: 2824-2432, 1997.
33. Lee SJ and McPherron AC: Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306-9311, 2001.
34. Suryawan A, Frank JW, Nguyen HV and Davis TA: Expression of the TGF-beta family of ligands is developmentally regulated in skeletal muscle of neonatal rats. Pediatr Res 59: 175-179, 2006.
35. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G and Vogelstein B: Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28: 184-187, 2001.
36. Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ and Hardwick JC: The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134: 1332-1341, 2008.
37. Wen XZ, Akiyama Y, Baylin SB and Yuasa Y: Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25: 2666-2673, 2006.
38. Mahoney SE, Yao Z, Keyes CC, Tapscott SJ and Diede SJ: Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 7: 400-408, 2012.
39. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
40. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.
41. Pregizer S and Mortlock DP: Control of BMP gene expression by long-range regulatory elements. Cytokine Growth Factor Rev 20: 509-515, 2009.
42. Chandler RL, Chandler KJ, McFarland KA and Mortlock DP: Bmp2 transcription in osteoblast progenitors is regulated by a distant 3′ enhancer located 156.3 kilobases from the promoter. Mol Cell Biol 27: 2934-2951, 2007.
43. Jabbour E, Issa JP, Garcia-Manero G and Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112: 2341-2351, 2008.
44. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999.
45. Mossman D, Kim KT and Scott RJ: Demethylation by 5-aza-2′- deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10: 366, 2010.
46. Tachibana K, Takeda K and Shiraishi M.: 5-Aza-2′-deoxycytidine reactivates the CDH1 gene without influencing the methylation of the entire CpG island or histone modification in a human cancer cell line. Proc Japan Acad 80: 342-348, 2004.
47. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL and Ghosh Choudhury G: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272: 705-711, 2000.
48. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY and Carethers JM: Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291: G135-G145, 2006.
49. Wen XZ, Miyake S, Akiyama Y and Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 316: 100-106, 2004.
50. Cip1/Waf1. Am J Physiol Endocrinol Metab 284: E972-E979, 2003.
51. Du Y and Yip H: Effects of bone morphogenetic protein 2 on Id expression and neuroblastoma cell differentiation. Differentiation 79: 84-92, 2010.
52. Ogata T, Wozney JM, Benezra R and Noda M: Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc Natl Acad Sci USA 90: 9219-9222, 1993.
53. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ and Yuan JX: Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 285: L740-L754, 2003.
54. Iantosca MR, McPherson CE, Ho SY and Maxwell GD: Bone morphogenetic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J Neurosci Res 56: 248-258, 1999.
55. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.